Sichenzia Ross Ference LLP Represents Aegis Capital in $5.5 Million Follow-On Offering of CEL-SCI Corporation Common Stock

Press Release – New York, NY – December 30, 2019 – Sichenzia Ross Ference LLP announced today that it represented Aegis Capital Corp. as sole book runner in the follow-on offering of 606,395 shares of the common stock of CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, at an offering price of $9.07 per share, for gross proceeds of $5.5 million. Pursuant to the terms of the underwriting agreement, Aegis has been granted a 45-day option to purchase up to an additional 90,959 shares of CEL-SCI common stock to cover over-allotments.

The Sichenzia Ross Ference LLP team was led by partners Darrin Ocasio, Avital Perlman and Marcelle Balcombe and associates Grant Levine and Jacob Tabman.